Sweden· SE-20241128000167
Remsima 40 mg/ml Koncentrat till infusionsvätska, lösning
A medicinal product containing infliximab, registered in Sweden by Celltrion Healthcare Hungary Kft.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Infliximab
- Manufacturer
- Celltrion Healthcare Hungary Kft
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20241128000167
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Infliximab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaREMSIMACelltrion Healthcare Hungary Kft., Budapest
- NorwayRemsimaCelltrion Healthcare Hungary Kft.
- BelgiumRemsima 40 mg/mlCelltrion Healthcare Hungary
- PolandRemsimaCelltrion Healthcare Hungary Kft.
- IrelandRemsima 40 mg/mL concentrate for solution for infusionCelltrion Healthcare Hungary Kft.
- FinlandRemsimaCelltrion Healthcare Hungary Kft.
- IcelandRemsimaCelltrion Healthcare Hungary Kft.
- SwitzerlandFlixabi
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Remicade, Remsima
- Liechtenstein · Remicade, Remsima
- Norway · Remicade, Remsima
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c9bfe41a-bf74-4035-a472-e4ab1427e9bf GET /v1/drugs/c9bfe41a-bf74-4035-a472-e4ab1427e9bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"DHPC",
"Dispensbeslut",
"EPAR",
"EMA"
],
"se_npl_id": "20241128000167",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20241128000167",
"product_doc_link": "https://docetp.mpa.se/LMF/Remsima-%28infliximab%29-DHPC-2025-12-15_09001bee84de24f4.pdf"
}See everything about infliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.